| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) (NCT06685692) | Aldeyra Therapeutics, Inc. | 2024-11-04 |
| A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (NCT06493604) | Aldeyra Therapeutics, Inc. | 2024-06-24 |
| A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (NCT06424444) | Aldeyra Therapeutics, Inc. | 2024-04-29 |
| A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) (NCT05717920) | Aldeyra Therapeutics, Inc. | 2023-02-15 |
| Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome (NCT05599815) | Aldeyra Therapeutics, Inc. | 2023-01-01 |
| A Study in Subjects With Retinitis Pigmentosa (NCT05392179) | Aldeyra Therapeutics, Inc. | 2022-07-14 |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough (NCT05392192) | Aldeyra Therapeutics, Inc. | 2022-04-07 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease (NCT05424549) | Aldeyra Therapeutics, Inc. | 2022-03-09 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis (NCT05234554) | Aldeyra Therapeutics, Inc. | 2022-01-21 |
| A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels (NCT05487404) | Aldeyra Therapeutics, Inc. | 2021-11-15 |
| An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber (NCT05102409) | Aldeyra Therapeutics, Inc. | 2021-09-09 |
| The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease (NCT05062330) | Aldeyra Therapeutics, Inc. | 2021-08-28 |
| A Clinical Trial to Assess Subjects With Dry Eye Disease. (NCT04971031) | Aldeyra Therapeutics, Inc. | 2021-06-15 |
| A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis (NCT04908514) | Aldeyra Therapeutics, Inc. | 2021-05-07 |
| A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. (NCT04847544) | Aldeyra Therapeutics, Inc. | 2021-03-31 |
| A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease (NCT04735393) | Aldeyra Therapeutics, Inc. | 2021-01-26 |
| A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) (NCT04728711) | Aldeyra Therapeutics, Inc. | 2021-01-09 |
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease (NCT04674358) | Aldeyra Therapeutics, Inc. | 2020-11-21 |
| The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy (NCT04136366) | Aldeyra Therapeutics, Inc. | 2019-11-15 |
| A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease (NCT03916042) | Aldeyra Therapeutics, Inc. | 2019-04-23 |
| The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (NCT03879863) | Aldeyra Therapeutics, Inc. | 2019-04-16 |
| A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (NCT03709121) | Aldeyra Therapeutics, Inc. | 2018-10-02 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis (NCT03660878) | Aldeyra Therapeutics, Inc. | 2018-09-08 |
| RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) (NCT03445650) | Aldeyra Therapeutics, Inc. | 2018-07-18 |
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis (NCT03494504) | Aldeyra Therapeutics, Inc. | 2018-03-30 |
| A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease (NCT03404115) | Aldeyra Therapeutics, Inc. | 2018-01-02 |